<DOC>
	<DOCNO>NCT01296932</DOCNO>
	<brief_summary>Adult patient chronic lymphocytic leukaemia experience relapse least two prior treatment regimen may enrol trial . The trial examine whether monotherapy BI 836826 safe tolerable escalate dose level .</brief_summary>
	<brief_title>BI836826 Dose Escalation Relapsed Chronic Lymphocytic Leukaemia ( CLL )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>Inclusion criterion : 1 . Diagnosis relapse refractory chronic lymphocytic leukaemia . 2 . At least two prior treatment regimens chronic lymphocytic leukaemia . 3 . At least one criterion active disease define International Workshop CLL . 4 . Absolute lymphocyte count low 200 x 10^9/l . 5 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 , 1 2 . 6 . Age 18 year old . 7 . Written inform consent consistent International Conference Harmonisation Good Clinical Practice ( ICHGCP ) guideline local legislation . Exclusion criterion : 1 . Treatment anti CD 20 therapy within 4 week , alemtuzumab within 8 week , cytotoxic antileukemia therapy within 2 week , Ibrutinib Idelalisib within 1 week prior first administration trial drug . 2 . Prior allogeneic stem cell transplantation . 3 . Active autoimmune haemolytic anemia . 4 . Active autoimmune thrombocytopenia . 5 . Known transformation aggressive Bcell malignancy . 6 . Concurrent treatment relevant dose systemic glucocorticosteroids . 7 . Prior history malignancy chronic lymphocytic leukaemia ( exception rule define clinical trial protocol ) . 8 . Aspartate aminotransferase alanine aminotransferase &gt; 2.5 x upper limit normal . 9 . Total bilirubin &gt; 1.5 x upper limit normal . 10 . Absolute Neutrophil Count &lt; 1.000/µl . 11 . Platelets &lt; 25.000/µL . 12 . Estimated Glomerular Filtration Rate &lt; 45 mL/min . 13 . Proteinuria Common Terminology Criteria Adverse Events ( CTCAE ) grade 2 high . 14 . Significant concurrent disease . 15 . Any infectious disease require treatment time enrolment within previous 2 week . 16 . Hepatitis B C. 17 . Human Immunodeficiency Virus ( HIV ) infection . 18 . Cytomegalovirus ( CMV ) viremia . 19 . Women childbearing potential use highly effective method birth control trial one year last dose . 20 . Pregnancy breast feed . 21 . Known suspect active alcohol drug abuse . 22 . Treatment another investigational drug within past four week start therapy concomitantly trial . 23 . Prior treatment BI 836826 . 24 . Patients unable comply protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>